• Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=29156680).
  
• Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=29156680; PubMed=30737244).
  
• Mutation; HGNC; 9801; RAC1; Simple; p.Asp63Val (c.188A>T); Zygosity=Heterozygous (PubMed=30737244).
  
• Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).
  

PubMed=10946899; DOI=10.1210/jcem.85.8.6732
Kurebayashi J., Tanaka K., Otsuki T., Moriya T., Kunisue H., Uno M., Sonoo H.
All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1.
J. Clin. Endocrinol. Metab. 85:2889-2896(2000)

CLPUB00144
Kurebayashi J., Tanaka K., Yamamoto Y., Okubo S., Sonoo H.
Human epidermal growth factor receptor 1 and thrombospondin-1 in thyroid cancer.
(In) Trends in thyroid cancer research. Horizons in cancer research, Vol. 37; Milton C.A. (eds.); pp.89-116; Nova Science Publishers; Hauppauge (2007)

PubMed=18713817; DOI=10.1210/jc.2008-1102
Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. III, Smallridge R.C., Haugen B.R.
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
J. Clin. Endocrinol. Metab. 93:4331-4341(2008)

PubMed=23833040; DOI=10.1210/jc.2013-2383
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)

PubMed=25675381; DOI=10.1210/jc.2014-2764
von Roemeling C.A., Marlow L.A., Pinkerton A.B., Crist A., Miller J., Tun H.W., Smallridge R.C., Copland J.A. III
Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target.
J. Clin. Endocrinol. Metab. 100:E697-E709(2015)

PubMed=29156680; DOI=10.18632/oncotarget.21262
Antonello Z.A., Hsu N., Bhasin M., Roti G., Joshi M., Van Hummelen P., Ye E., Lo A.S., Karumanchi S.A., Bryke C.R., Nucera C.
Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF(V600E).
Oncotarget 8:84743-84760(2017)

PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953
Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C., Copland J.A. III, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Clin. Cancer Res. 25:3141-3151(2019)